Lobectomy has been the standard surgical procedure for clinical stage IA non-small cell lung cancer (NSCLC) since the results of a randomized trial in 1995. However, recent phase III trials have demonstrated the efficacy of segmentectomy for small NSCLC. Segmentectomy has become one of the standard treatments for peripheral lung cancers with a tumor diameter of ≤2 cm and further expansion of the indication for segmentectomy is considered. We planned this trial to confirm the non-inferiority of segmentectomy to lobectomy in terms of overall survival in patients with solid-predominant NSCLC with ground-glass opacity and > 2 cm and ≤ 3 cm in tumor diameter. Pure-solid tumors will be excluded because of their highly malignant characteristics. The primary endpoint is overall survival. A total of 515 patients from 53 institutions will be enrolled over 5 years. The trial has been registered in the Japan Registry of Clinical Trials (study number: jRCTs1030240027).
Keywords: ground glass opacity; non-small cell lung cancer; segmentectomy; solid-predominant tumor; thin-slice computed tomography.
© The Author(s) 2025. Published by Oxford University Press. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.